Which agents are used to treat mucosal bleeding in bleeding disorders?

• A. Vitamin K and fresh frozen plasma
• B. Tranexamic acid or aminocaproic acid; desmopressin for vWD; factor concentrates as needed.
• C. Platelet transfusions alone
• D. Anticoagulants such as heparin during mucosal bleeding

Answer: (B)

In mucosal bleeding, the goal is to stabilize clots at surfaces where fibrinolysis is particularly active and to correct any specific factor deficiencies that underlie the bleeding. Antifibrinolytics like tranexamic acid or aminocaproic acid inhibit the breakdown of clots by blocking plasmin formation, which helps keep clots intact where mucous membranes and epithelium are involved. They’re especially useful for bleeding from the mouth, nose, or gums, and can be used systemically or as a local mouthwash around dental procedures.

Desmopressin is especially helpful when von Willebrand disease is involved. It prompts the release of stored von Willebrand factor and factor VIII from endothelial cells, improving platelet adhesion and the formation of a stable fibrin clot. This makes it a good choice for mild vWD and certain mucosal bleeds where primary hemostasis needs a boost.

When there’s a confirmed deficiency of a specific factor, replacing that factor with concentrates is the most direct remedy. Factor concentrates provide the exact missing factor (for example, factor VIII in hemophilia A or factor IX in hemophilia B, and vWF-containing concentrates for vWD when DDAVP isn’t enough or isn’t appropriate). These address the underlying cause of impaired coagulation and are used for more significant or persistent mucosal bleeding.

This combination—stabilizing clots with antifibrinolytics, boosting vWF/FVIII when appropriate with DDAVP, and replacing specific factors with concentrates—targets the common mechanisms driving mucosal bleeding in bleeding disorders.